What Sarepta Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 2 |
| Total trades | 5 | 50 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 756,104 | 1,474,888 |
| Disposed | 81,519 | 137,105 |
| Net activity | +674,585 | +1,337,783 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Rodino-Klapac Louise | President, R&D and Tech Ops | Sep 04 | Withheld — tax / exercise cost · F | −21,423 | $22.22 | −$476K | 203,900 |
| Rothfuss Cristin | EVP, General Counsel | Sep 04 | Withheld — tax / exercise cost · F | −22,025 | $22.22 | −$489K | 115,519 |
| Wong Ryan Ho-Yan | Chief Financial Officer | Sep 04 | Withheld — tax / exercise cost · F | −13,272 | $22.22 | −$295K | 121,792 |
| Estepan Ian Michael | Chief Operating Officer | Sep 04 | Withheld — tax / exercise cost · F | −24,799 | $22.22 | −$551K | 177,184 |
| Severino Michael | Chief Executive Officer | Jul 28 | Grant / award · A | +756,104 | — | — | 756,104 |
| Connelly Deirdre P | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 22,100 |
| Barry Richard | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 2,983,542 |
| Chambers Michael Andrew | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 27,535 |
| Nicaise Claude | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 48,407 |
| Mayo Stephen | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 18,640 |
| Behrens M Kathleen | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 214,357 |
| Wigzell Hans Lennart Rudolf | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 42,098 |
| Boor Kathryn Jean | Director | Jun 04 | Grant / award · A | +16,875 | — | — | 25,138 |
| Mayo Stephen | Director | Mar 12 | Sale for tax withholding · S | −7,239 | $17.02 | −$123K | 1,765 |
| Rothfuss Cristin | EVP, General Counsel | Mar 11 | Withheld — tax / exercise cost · F | −974 | $17.03 | −$16.6K | 137,544 |
| Wong Ryan Ho-Yan | Chief Financial Officer | Mar 11 | Withheld — tax / exercise cost · F | −256 | $17.03 | −$4.36K | 135,064 |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Mar 11 | Withheld — tax / exercise cost · F | −948 | $17.03 | −$16.1K | 225,323 |
| Estepan Ian Michael | Chief Operating Officer | Mar 11 | Withheld — tax / exercise cost · F | −1,097 | $17.03 | −$18.7K | 201,983 |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Mar 09 | Withheld — tax / exercise cost · F | −895 | $16.95 | −$15.2K | 226,271 |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Mar 09 | Withheld — tax / exercise cost · F | −504 | $16.95 | −$8.54K | 227,166 |
Loading...
